FIGURE

Figure 3

ID
ZDB-FIG-200513-3
Publication
Griffin et al., 2020 - Phenotype-Based Screening of Synthetic Cannabinoids in a Dravet Syndrome Zebrafish Model
Other Figures
All Figure Page
Back to All Figure Page
Figure 3

Electrophysiological assay for compounds identified in the locomotion-based screening assay. (A) Local field potential (LFP) recordings were obtained with an glass micro-electrode placed under visual guidance in the midbrain of agar-immobilized scn1lab larvae that had previously showed reduced seizure-like behavior in the locomotion assay. Representative examples of events classified as interictal- or ictal-like are shown. Scale bars: 1 mV, 0.5 s, (B) Bar graphs show the frequency of epileptiform events in a 10 min recording epoch for scn1lab larvae exposed to DMSO vehicle (scn1lab mutants; n = 17), JWH 018 N-(5-chloropentyl) analog (compound #10521; n = 10), JWH 018 N-(2-methylbutyl) isomer (compound #10690; n = 12), 5-fluoro PB-22 5-hydroxyisoquinoline isomer (compound #14550; n = 11), 5-fluoro ADBICA (compound #14766; n = 13), JWH 018 adamantyl analog (compound #9000799; n = 13), and AB-FUBINACA 3-fluorobenzyl isomer (compound #90001523; n = 11). Mean ± SEM and individual data points are shown. One-way analysis of variance with Dunnet's multiple comparisons was used to test for significance. **p < 0.001; *** p < 0.0001. (C) Representative electrophysiology traces (10 min) are shown for SC compounds 10521, 10690, 14550, 14766, 9000799, and 900015323 compared to an scn1lab mutant zebrafish (red). Scale bars: 1 mV, 10 s.

Expression Data

Expression Detail
Antibody Labeling
Phenotype Data

Phenotype Detail
Acknowledgments
This image is the copyrighted work of the attributed author or publisher, and ZFIN has permission only to display this image to its users. Additional permissions should be obtained from the applicable author or publisher of the image. Full text @ Front Pharmacol